2025
SJR Q2
JCR Q1 · 4,1
245 matched articles
SCIE
Journal detail
Clinical Lymphoma, Myeloma and Leukemia
- Publisher
- Elsevier Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
2152265021522669
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,615
- Quartile Q2
- H-Index 71
- Cites/doc 2,7
- Docs (3y) 1.077
- Cites (3y) 1.413
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,1
- 5Y JIF 2,8
- JCI 0,56
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q3
- Hematology Q2
- Oncology Q3
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q1 | 0,615 | 4,1 | 2,8 | 0,56 | Q2 | 71 |
| 2024 | Q3 | Q2 | 0,513 | 2,7 | 2,4 | 0,49 | Q3 | 68 |
| 2023 | Q3 | Q2 | 0,548 | 2,7 | 2,4 | 0,48 | Q3 | 68 |
| 2022 | Q2 | Q3 | 0,758 | 2,7 | 2,5 | 0,44 | Q3 | 68 |
| 2021 | Q2 | Q3 | 0,778 | 2,8 | 2,6 | 0,45 | Q3 | 68 |
| 2020 | Q2 | Q3 | 0,94 | 3,2 | 2,9 | 0,5 | Q3 | 68 |
| 2019 | Q2 | Q3 | 0,819 | 2,3 | 2,2 | 0,48 | Q3 | 68 |
| 2018 | — | Q3 | — | 2,3 | 2,2 | 0,5 | Q3 | — |
| 2017 | Q2 | Q3 | 0,895 | 2,3 | 2,2 | 0,49 | Q3 | 68 |
| 2016 | Q2 | Q3 | 0,772 | 2,5 | 2,2 | — | — | 68 |
| 2015 | Q2 | Q3 | 0,879 | 2,3 | 2,1 | — | — | 68 |
| 2014 | Q2 | Q3 | 0,82 | 2 | 1,7 | — | — | 68 |
| 2013 | Q2 | Q3 | 0,797 | 1,9 | 1,7 | — | — | 68 |
| 2012 | Q2 | Q3 | 0,839 | 1,7 | 1,5 | — | — | 68 |
| 2011 | Q2 | Q3 | 0,89 | 1,9 | 1,6 | — | — | 68 |
| 2010 | Q2 | Q3 | 0,671 | 2 | 1,8 | — | — | 68 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | HEMATOLOGY | SCIE | Q1 | Q2 | 25/103 |
| 2025 | ONCOLOGY | SCIE | Q2 | Q3 | 111/333 |
| 2024 | HEMATOLOGY | SCIE | Q2 | Q3 | 37/99 |
| 2024 | ONCOLOGY | SCIE | Q3 | Q3 | 171/328 |
| 2023 | HEMATOLOGY | SCIE | Q2 | Q3 | 35/97 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 163/322 |
| 2022 | HEMATOLOGY | SCIE | Q3 | Q3 | 52/79 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q3 | 173/241 |
| 2021 | HEMATOLOGY | SCIE | Q3 | Q3 | 56/78 |
| 2021 | ONCOLOGY | SCIE | Q4 | Q3 | 192/245 |
| 2020 | HEMATOLOGY | SCIE | Q3 | Q3 | 41/76 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q3 | 173/242 |
| 2019 | HEMATOLOGY | SCIE | Q3 | Q3 | 47/76 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q3 | 183/244 |
| 2018 | HEMATOLOGY | SCIE | Q3 | Q3 | 49/73 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q3 | 167/230 |
| 2017 | HEMATOLOGY | SCIE | Q3 | Q3 | 42/71 |
| 2017 | ONCOLOGY | SCIE | Q3 | Q3 | 164/223 |
| 2016 | HEMATOLOGY | SCIE | Q3 | — | 38/70 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 137/217 |
| 2015 | HEMATOLOGY | SCIE | Q3 | — | 45/70 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 136/213 |
| 2014 | HEMATOLOGY | SCIE | Q3 | — | 48/68 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 150/211 |
| 2013 | HEMATOLOGY | SCIE | Q3 | — | 47/68 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 142/203 |
| 2012 | HEMATOLOGY | SCIE | Q3 | — | 48/67 |
| 2012 | ONCOLOGY | SCIE | Q4 | — | 148/197 |
| 2011 | HEMATOLOGY | SCIE | Q3 | — | 47/68 |
| 2011 | ONCOLOGY | SCIE | Q3 | — | 129/196 |
| 2010 | HEMATOLOGY | SCIE | Q3 | — | 46/66 |
| 2010 | ONCOLOGY | SCIE | Q3 | — | 118/185 |